Dentsply Sirona (NASDAQ:XRAY) saw unusually large options trading on Monday. Stock investors acquired 944 call options on the stock. This represents an increase of approximately 973% compared to the average volume of 88 call options.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. NuWave Investment Management LLC acquired a new stake in shares of Dentsply Sirona in the 4th quarter valued at about $121,000. Focused Wealth Management Inc boosted its position in shares of Dentsply Sirona by 79.2% in the 4th quarter. Focused Wealth Management Inc now owns 2,600 shares of the medical instruments supplier’s stock valued at $171,000 after purchasing an additional 1,149 shares during the period. Stock Yards Bank & Trust Co. acquired a new stake in shares of Dentsply Sirona in the 4th quarter valued at about $203,000. Capital One National Association acquired a new stake in shares of Dentsply Sirona in the 4th quarter valued at about $204,000. Finally, Boston Common Asset Management LLC acquired a new stake in shares of Dentsply Sirona in the 4th quarter valued at about $212,000. 97.89% of the stock is owned by hedge funds and other institutional investors.
NASDAQ:XRAY opened at $49.48 on Tuesday. The stock has a market cap of $11,218.35, a PE ratio of 18.60, a price-to-earnings-growth ratio of 2.17 and a beta of 1.26. Dentsply Sirona has a 1 year low of $48.25 and a 1 year high of $68.98. The company has a quick ratio of 1.45, a current ratio of 2.10 and a debt-to-equity ratio of 0.24.
The company also recently announced a quarterly dividend, which was paid on Friday, April 13th. Investors of record on Thursday, March 29th were given a $0.0875 dividend. The ex-dividend date was Wednesday, March 28th. This represents a $0.35 dividend on an annualized basis and a dividend yield of 0.71%. Dentsply Sirona’s dividend payout ratio (DPR) is presently 13.16%.
Several brokerages have weighed in on XRAY. Cleveland Research restated a “hold” rating on shares of Dentsply Sirona in a report on Thursday, April 5th. JPMorgan Chase cut their price target on Dentsply Sirona from $75.00 to $70.00 and set an “overweight” rating on the stock in a report on Monday, March 5th. Jefferies Group restated a “buy” rating on shares of Dentsply Sirona in a report on Monday, April 16th. Barrington Research restated an “outperform” rating and set a $70.00 price target (down previously from $73.00) on shares of Dentsply Sirona in a report on Monday, March 5th. Finally, HC Wainwright set a $63.00 price objective on Dentsply Sirona and gave the stock a “hold” rating in a research report on Monday, March 5th. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the company. Dentsply Sirona has a consensus rating of “Hold” and an average target price of $67.36.
About Dentsply Sirona
DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
Receive News & Ratings for Dentsply Sirona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dentsply Sirona and related companies with MarketBeat.com's FREE daily email newsletter.